Imprimis Pharmaceuticals, Inc. and DPT Labs have entered an agreement under which DPT will supply Imprimis with quantities of its active topical anti-inflammatory drug, Impracor, for Phase III trials. Impracor is the first drug to be developed using Imprimis’s Accudel topical delivery technology.

Imprimis Pharmaceuticals, Inc. chief executive officer, Mark L. Baum said, “Imprimis is pleased to have entered into an agreement for manufacturing our active Impracor clinical supplies from DPT Labs, a worldwide leader in the contract formulation and production of semi-solid pharmaceutical products. We are very confident that choosing DPT Labs will provide Imprimis with the best semi-solid production capabilities in the United States and the flexibility of scale to manufacture Impracor. The DPT agreement means that Imprimis is one step closer to our goal to get Impracor approved for sale and into the hands of patients who are suffering from musculoskeletal pain and inflammatory conditions.”

 “We are delighted to be chosen by Imprimis and we look forward to leveraging our expertise in semi-solids and liquids to support further execution of clinical development and manufacturing strategies for Impracor,” said Paul Josephs, DPT senior vice president sales, marketing and corporate development.